Business Context and Reporting Period
Company: Alnylam Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 14, 2015
Event: Material modification to rights of security holders and amendments to articles of incorporation.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on corporate governance actions regarding preferred stock.
Material Changes
- Expiration of Rights Plan: The Company's stockholder rights plan expired on July 13, 2015.
- Certificate of Elimination: On July 14, 2015, the Company filed a Certificate of Elimination with the Delaware Secretary of State.
- Stock Status Change: 125,000 shares of unissued Series A Junior Participating Preferred Stock (designated in 2005) were returned to the status of authorized but unissued shares without specific series designation or rights.
- Administrative Actions: The Company will deregister the related preferred stock purchase rights under the Securities Exchange Act of 1934 and delist them from the Nasdaq Global Select Market.
Guidance, Outlook, and Risks
Impact on Common Stock: The administrative actions taken regarding the preferred stock purchase rights will have no effect on the Company's common stock, which remains listed on the Nasdaq Global Select Market.
Forward-Looking Statements: The filing contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially. Investors are directed to the Company's most recent Quarterly Report on Form 10-Q (filed May 8, 2015) for additional risk disclosures.
Investor Verification Checklist
- Confirm the expiration date of the stockholder rights plan (July 13, 2015).
- Verify the filing of the Certificate of Elimination with the Delaware Secretary of State.
- Review the status of the 125,000 shares of Series A Junior Participating Preferred Stock as authorized but unissued.
- Check for the deregistration of preferred stock purchase rights under the Securities Exchange Act of 1934.
- Confirm that the Company's common stock listing on the Nasdaq Global Select Market remains unaffected.